Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Thursday 02 December, 2021

C4X Discovery

Clive Dix awarded Honorary Fellowship

RNS Number : 2999U
C4X Discovery Holdings PLC
02 December 2021
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Clive Dix awarded Honorary Fellowship by the British Pharmacological Society

 

2 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that its Chief Executive Officer, Dr Clive Dix BSc PhD HonFBPhS, has been awarded an Honorary Fellowship by the British Pharmacological Society in recognition of sustained excellence and leadership in science, healthcare, and public service.

 

Eva-Lotta Allan, Chairman of C4X Discovery, said: "The award of an Honorary Fellowship by the prestigious British Pharmacological Society is testament to Clive's accomplishments and the important work he continues to do for the British healthcare industry and further afield.  As part of the team here at C4XD, we are very proud to be working with Clive.  Throughout his career, Clive has strived to promote British science at its best and this award shines a light on the important contribution Clive has made.  Looking at the past year alone, he served as Interim Chair of the UK Vaccines Taskforce, where he was integral to the successful selection and roll-out of vaccines in the UK. Under his leadership we also signed our second deal, this time with Sanofi for total value up to €414 million. All of these achievements have only been possible because of Clive's tireless determination to deliver life changing medicines to patients in need, and we congratulate him on this well-deserved Honorary Fellowship."

 

The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. It leads the way in the research and application of pharmacology around the world, with members from more than 60 countries worldwide. Honorary Fellows are elected for life by the British Pharmacological Society in recognition of sustained excellence and leadership in science, healthcare, and public service. The Honorary Fellowship includes Nobel Laureates, international prize-winners, long-standing members of the Society, and those who have advanced the disciplines of Pharmacology, Clinical Pharmacology and Therapeutics through research, leadership and contribution to the British Pharmacological Society.

 

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977

C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATBBTTMTMMTTB

a d v e r t i s e m e n t